Todos os estudos
Ativo, mas não recrutandoFASE2INTERVENCIONISTA

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

This study is looking at a new medicine called acalabrutinib to treat Waldenström Macroglobulinemia (WM), which is a rare type of blood cancer. Researchers want to find out if acalabrutinib is safe, how it affects the body, and how well it works in people with WM. WM causes the body to make too much of a certain protein and can lead to problems. Current treatments exist, but scientists are always looking for new and better options. Acalabrutinib is a type of drug that targets a specific pathway in cancer cells, similar to another approved medicine, but it's new and needs careful testing. This study will help us understand if it could be a helpful treatment for WM.

Em resumo

Status
Ativo, mas não recrutando
Fase
FASE2
Patrocinador
Acerta Pharma BV
Meta de inscrição
107
Iniciar
11 Sep 2014
Conclusão estimada
31 Dez 2026

Resultados

Resultados deste estudo

Publicado April 2020

Os resultados foram publicados para este estudo.

Resultado primário
Overall Response Rate (ORR) of Acalabrutinib in Subjects as Assessed by Investigator Per IWWM 6th Criteria
ORR defined as the rate of subjects achieving a Miner Response (MR) or better including complete response (CR), very good partial response (VGPR), partial response (PR) and MR; The definition of responses are evaluated by investigators using both Modified 6th criteria (refer to protocol table 4-2 , 4-3) and Modified 3rd International Workshop of Waldenström Macroglobulinemia (IWWM) criteria (refer to protocol table 4-4 and table 4-5 for definition). For Modified 6th criteria, MR is defined as (1) monoclonal IgM protein is detectable, (2) no new signs or symptoms of active disease, (3) and patient has \>=25% but \< 50% reduction in serum monoclonal IgM level from baseline. PR and VGPR both require (1) and (2) as MR, but PR also requires the \>=50% and \<90% reduction in serum monoclonal IgM level as well as reduction in extramedullary disease. VGPR requires \>= 90% reduction in serum IgM and complete resolution of extramedullary disease.
Resultados completos no registro

Sobre o que é este estudo?

Waldenström Macroglobulinemia (WM) is a rare type of cancer that affects certain white blood cells. These cells produce a protein called IgM, and in WM, too much IgM is made. This can cause the blood to become thick and lead to various health problems. While there are treatments available for WM, scientists are always working to find new and more effective options, or ones with fewer side effects.

This study is focusing on a new medicine called acalabrutinib. This drug works by blocking a specific signal inside the cancer cells, which helps stop them from growing and multiplying. You might have heard of a similar medication called ibrutinib, which is already used to treat WM and other similar conditions. Acalabrutinib is designed to work in a similar way but is a newer version that shows promise in early tests.

The main goals of this study are to carefully check how safe acalabrutinib is for people with WM. Researchers also want to understand how the body handles the medicine – how it's absorbed, used, and cleared from the body. Finally, and very importantly, they want to see if acalabrutinib is effective at treating WM and helping patients feel better or slow down the disease’s progress. This type of study (called a Phase 2 study) is a crucial step in bringing new medicines to patients.

Pontos principais

  • The study is testing a new medicine, acalabrutinib, for Waldenström Macroglobulinemia (WM).
  • It aims to check the safety, how the body handles it, and if it helps treat WM.
  • Participation requires regular clinic visits and health checks.
  • It's for people with WM who have either been previously treated or are newly diagnosed but cannot have standard chemotherapy.
  • Você pode parar de participar a qualquer momento.

Quem pode ser elegível?

To join this study, you need to be at least 18 years old. The study is open to both men and women. You must have a confirmed diagnosis of Waldenström Macroglobulinemia (WM).

If you've already had treatment for WM, you can join if your WM has come back or hasn't responded well to at least one previous treatment. If you haven't been treated for WM before, you can join if you need treatment and either don't want to receive standard chemotherapy combined with immunotherapy, or if other health issues mean you can't have those standard treatments. Your WM also needs to show certain signs, like a high level of a protein called IgM in your blood, or specific sized swollen lymph nodes.

There are also some general health requirements. For example, you need to be well enough to take part in all the study activities. There are other reasons why you might not be able to join, such as having certain other serious medical conditions or recent cancers (other than some common skin cancers or very early-stage cervical cancer). The medical team will check all your health details carefully to make sure the study is safe and right for you.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você tem 18 anos ou mais?
  2. Do you have a confirmed diagnosis of Waldenström Macroglobulinemia?
  3. If you've had WM treatment before, has your WM come back or not responded well?
  4. If you've never been treated for WM, are you unable to have standard chemotherapy or prefer not to?
  5. Are you able to swallow capsules without difficulty?
  6. Do you feel well enough to attend regular clinic visits?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part in this study, you will be given the study medicine, acalabrutinib, which you will take by mouth as capsules. The study will involve regular visits to the clinic so the medical team can monitor your health and how you're responding to the treatment. These visits will include various assessments like blood tests to check how the medicine is working and for any side effects, as well as general health check-ups.

You will need to be able to swallow capsules without difficulty. During the study, it's very important for women who can get pregnant to use highly effective contraception, and to continue doing so for 2 days after your last dose of the study medicine. The total duration of your participation, including how long you take the medicine and any follow-up visits, will be explained in detail by the study team. They will also discuss all the specific procedures and the time commitment involved.

Riscos e benefícios potenciais

Taking part in any clinical study has potential benefits and risks. You might benefit from receiving a new treatment that could help manage your Waldenström Macroglobulinemia if existing therapies haven't worked well or if you can't have standard treatments. However, it's important to remember that this is a new medicine, and its full effects are still being studied. There's no guarantee it will work for everyone, and it might not work for you. Potential risks include side effects from the medicine, which will be carefully monitored by the study team. These could range from mild to more serious, and the team will discuss all known possible side effects with you before you agree to participate. You will also have many tests and procedures as part of the study. It is very important to remember that you can choose to leave the study at any time, for any reason, without it affecting your medical care.

Locations (38)

  • Site de Pesquisa
    Código postal verificado
    Santa Barbara, Estados Unidos
  • Site de Pesquisa
    Código postal verificado
    Aurora, Estados Unidos
  • Site de Pesquisa
    Código postal verificado
    Washington D.C., Estados Unidos
  • Site de Pesquisa
    Código postal verificado
    Minneapolis, Estados Unidos
  • Site de Pesquisa
    Código postal verificado
    Nova Iorque, Estados Unidos
  • Site de Pesquisa
    Código postal verificado
    Nashville, Estados Unidos
  • Site de Pesquisa
    Código postal verificado
    Austin, Estados Unidos
  • Site de Pesquisa
    Código postal verificado
    Bedford, United States
  • Site de Pesquisa
    Código postal verificado
    Houston, Estados Unidos
  • Site de Pesquisa
    Código postal verificado
    Vancouver, United States
  • Site de Pesquisa
    Código postal verificado
    Aurillac, France
  • Site de Pesquisa
    Apenas cidade
    Clermond Ferrand, France

Perguntas frequentes

What is Waldenström Macroglobulinemia (WM)?

It's a rare type of blood cancer where your body makes too much of a specific protein, which can cause health issues.

What is acalabrutinib?

It's a new medicine being tested. It works by blocking a signal in cancer cells to stop them from growing.

Is acalabrutinib already approved for WM?

No, it's still being studied in clinical trials like this one to see if it's safe and effective for WM.

Will I get regular checks if I join?

Yes, you'll have regular visits, blood tests, and health checks to monitor your progress and safety.

Posso sair do estudo se mudar de ideia?

Absolutely, you can withdraw from the study at any time, and it won't affect your regular medical care.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.